Company intelligence / Profile preview

Pulmolite

Worcester, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Pulmolite is an early-stage biotechnology and medical device company focused on improving the early detection of lung cancer. The company is developing a proprietary fluorescence-based imaging technology designed to help clinicians differentiate between malignant and benign pulmonary nodules during bronchoscopy. By providing real-time, high-sensitivity diagnostic capabilities, Pulmolite aims to reduce the number of unnecessary invasive procedures and improve patient outcomes through earlier intervention. The technology is primarily intended for use in interventional pulmonology and thoracic surgery settings.

Therapeutic areas: OncologyPulmonology
Modalities: DeviceDiagnostic
Industry: Pathology

Beyond the preview

Go deeper on Pulmolite.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pulmolite.

Explore the full profile